#VisualAbstract: First-Line Sugemalimab Plus Chemotherapy Provides Survival Benefit in Advanced Gastric Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in Nature Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Click to read this study in The Lancet Oncology.
Click to read this study in the European Journal of Cancer.
Click to read this study in the Journal of Clinical Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in JAMA Oncology.
Click to read the study in the European Journal of Cancer.
1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone. 2. Severe ...
Click to read the study in the Journal of Clinical Oncology.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.